Oxular Doses First Patients in OXEYE Phase 2 Clinical Trial of Suprachoroidal OXU-001 as a Long-Acting Treatment for Diabetic Macular Edema
OXFORD, United Kingdom & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct 24, 2023--<a ...
OXFORD, United Kingdom & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct 24, 2023--<a ...
NANTES, France--(BUSINESS WIRE)--Oct 23, 2023--Regulatory News:<em>OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE)</em> today announced that first Phase 1 results for BI 770371, a novel anti-SIRPa monoclonal antibody evaluated in advanced solid tumors, ...
NEW YORK--(BUSINESS WIRE)--Oct 23, 2023--Flatiron Health today announced a new agreement to bring <a ...
HOUSTON--(BUSINESS WIRE)--Oct 23, 2023--<em>Kiromic BioPharma, Inc. (OTC PINK: KRBP) (鈥淜iromic鈥� or the 鈥淐ompany鈥�)</em>, a clinical-stage, fully-integrated biotherapeutics company using its proprietary DIAMOND 庐 artificial intelligence and data mining ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct 23, 2023--<a ...
ALAMEDA, Calif.--(BUSINESS WIRE)--Oct 22, 2023--<a ...